News
Read more VitroScan's micro-tumor test accurately predicts chemotherapy response for ovarian cancer patients
9 September 2025
VitroScan is proud to announce the publication of a study showing its 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.
Read more
Read more VitroScan awarded ~ 200k Leap Medical:Forge grant
22 April 2025
We are very pleased to announce that VitroScan has received a grant of approximately 200k Euros from leap:up. The grant is part of the medical:forge Leipzig accelerator program, based in Leipzig, Germany.
Read more
Read more 'Hoe maak je het?' bij VitroScan
15 January 2025
Het Leidse radiostation Sleutelstad stuurde verslaggever Gerry van Bakel van het programma ‘Kennismakers’ naar VitroScan voor de rubriek ‘Hoe maak je het?’
Read more
Read more VitroScan awarded €1.9M by Biotech Booster to deliver chemotherapy response prediction for ovarian cancer patients
25 November 2024
VitroScan has developed ChemoPredict™, a predictive tumor testing service that revolutionizes treatment options for ovarian cancer patients.
Read more
Read more VitroScan Welcomes Mayor Peter Heijkoop for a Visit
29 October 2024
We were honored to welcome Leiden's Mayor Peter Heijkoop to our VitroScan office, as part of his broader tour of the innovative companies at Leiden Bio Science Park.
Read more
Read more First patient included in ex vivo clinical trial for Imuno's BiTE targeting
20 September 2024
The collaboration between Imunotx and VitroScan is advancing to the first patient included in ex vivo clinical trial for Imuno's peptide MHC targeting T cell engagers.
Read more
Read more VitroScan presents at ESMO24: Chemo response prediction for lung, bladder, and ovarian cancer
15 September 2024
Dr Christi Steendam (Catharina ziekenhuis), dr Debbie Robbrecht (ErasmusMC), and dr. Nelleke Ottevanger (Radboudumc) present an ex vivo basket trial for chemotherapy response prediction at the ESMO conference in Barcelona.
Read more
Read more Near clinical testing translates into better informed decisions
10 May 2024
Testing Models or Patients...? A growing gap has emerged between research models in the lab and patients that require their new treatments. In a time of escalating costs, high attrition rates, limited resources and extended timelines we need to invest in highly translational research.
Read more
Read more AACR24 - Willemijn Vader presented VitroScan's most recent data!
22 April 2024
Willemijn Vader presented VitroScan's most recent data on NSCLC and ovarian cancer @AACR24!
Read more
Read more VitroScan's patient centric approach
12 December 2023
For the past year, VitroScan has been collaborating with nine exceptional Leiden-based startups as a part of the Leiden Bio Science Park Startup Booster project. Now, we're thrilled to announce the launch of our company video!
Read more
Read more Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer - VitroScan presents @ the AACR-NCI-EORTC meeting 2023
14 October 2023
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023, in Boston, Willemijn Vader presented our most recent results on 'Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer.
Read more
Read more InCephalo AG, University of Basel and VitroScan win Eurostars grant
9 October 2023
InCephalo AG, University of Basel and VitroScan receive competitive Eurostars grant (€2,3M) to accelerate the development of promising new drugs for Glioblastoma patients - CLEIO.
Read more